Latica Med

Company Overview

Snapshot

Founded in June 2023 by Eduard Papirov, Itzhak Fridman, and Sari Prutchi-Sagiv, Latica Med operates with 1–10 employees. The company has secured $200K in total capital across one funding round from one investor. Latica Med is preparing to commence a clinical trial to enhance IVF success rates.

Business overview

Latica Med is a medical devices company focused on developing novel, non-invasive, non-drug therapies for gynecology and other diseases to improve women's fertility. The company utilizes its proprietary patented Acoustic Pulse Technology (APT) device, designed for treating gynecological disorders. Latica Med's APT aims to prepare women for IVF by addressing root causes of infertility, including infections, implantation failures, endometrium thickness, and endometriosis. The company operates within the Health Tech & Life Sciences sector, specifically targeting Medical Devices and Medical Treatment & Therapeutics, serving patients globally.

Strategic signal

Latica Med is poised to commence a clinical trial aimed at enhancing IVF success rates, as announced in March 2025. This development signals a critical step towards validating their Acoustic Pulse Technology (APT) and advancing their mission to improve women's fertility through non-invasive treatments. For investors, this represents a significant de-risking event and a potential catalyst for future growth and market adoption in the femtech and fertility sectors.

Company Intelligence Q&A

What is Latica Med's core technology?

Latica Med's core technology is a proprietary patented Acoustic Pulse Technology (APT) device, specifically designed for treating gynecological disorders and improving women's fertility through non-invasive, non-drug therapy.

When was Latica Med founded and by whom?

Latica Med was founded in June 2023 by Eduard Papirov, Itzhak Fridman, and Sari Prutchi-Sagiv.

What is the primary focus of Latica Med's product development?

Latica Med's product development focuses on improving women's fertility by addressing root causes of infertility, such as infections, implantation failures, endometrium thickness, and endometriosis, particularly in preparation for IVF processes.

What is the current stage of Latica Med's product development?

Latica Med's product, Lati-A, is currently in the clinical trial stage, with the company set to commence a clinical trial soon to enhance IVF success rates, as announced in March 2025.

What was Latica Med's last disclosed funding event?

In April 2024, Latica Med secured pre-seed funding from PipelBiz.